Abstract
X-Chem has secured drug discovery pacts with two Japanese firms. In what X-Chem calls a transformative deal, Astellas Pharma will use X-Chem’s DNA-encoded libraries to find lead compounds against tough drug targets. X-Chem scores $16 million upfront, as well as research support and milestone payments throughout the multiyear deal. Separately, Ono Pharmaceutical has teamed with X-Chem to develop drug leads against oncology targets.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
